Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma | Zendy

Thierry Façon | Zendy; Shaji Kumar | Zendy; Torben Plesner | Zendy; Robert Z. Orlowski | Zendy; Philippe Moreau | Zendy; Nizar J. Bahlis | Zendy; Supratik Basu | Zendy; Hareth Nahi | Zendy; Cyrille Hulin | Zendy; Hang Quach | Zendy; Hartmut Goldschmidt | Zendy; Michael O’Dwyer | Zendy; Aurore Perrot | Zendy; Christopher P. Venner | Zendy; Katja Weisel | Zendy; Joseph R. Mace | Zendy; Noopur Raje | Zendy; Michel Attal | Zendy; Mourad Tiab | Zendy; Margaret Macro | Zendy; Laurent Frenzel | Zendy; Xavier Leleu | Zendy; Tahamtan Ahmadi | Zendy; Christopher Chiu | Zendy; Jianping Wang | Zendy; Rian Van Rampelbergh | Zendy; Clarissa Uhlar | Zendy; Rachel Kobos | Zendy; Ming Qi | Zendy; Saad Z. Usmani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Author(s) -

Thierry Façon,

Shaji Kumar,

Torben Plesner,

Robert Z. Orlowski,

Philippe Moreau,

Nizar J. Bahlis,

Supratik Basu,

Hareth Nahi,

Cyrille Hulin,

Hang Quach,

Hartmut Goldschmidt,

Michael O’Dwyer,

Aurore Perrot,

Christopher P. Venner,

Katja Weisel,

Joseph R. Mace,

Noopur Raje,

Michel Attal,

Mourad Tiab,

Margaret Macro,

Laurent Frenzel,

Xavier Leleu,

Tahamtan Ahmadi,

Christopher Chiu,

Jianping Wang,

Rian Van Rampelbergh,

Clarissa Uhlar,

Rachel Kobos,

Ming Qi,

Saad Z. Usmani

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1817249

Subject(s) - daratumumab , lenalidomide , dexamethasone , multiple myeloma , medicine , oncology

Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research